Trial Profile
Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications COVID-19 pneumonia; Pulmonary fibrosis
- Focus Therapeutic Use
- 04 Aug 2020 New source identified and integrated (Chinese Clinical Trial Register).
- 13 Apr 2020 New trial record